Biopharma Daily Stock Updates - 12/31/20

$XBI $140.78 (-2.29%) 📉

COVID:

$RDHL (-5.61%) - RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

https://ir.redhillbio.com/news-releases/news-release-details/redhill-biopharma-announces-positive-top-line-safety-and

$MRNA (-5.99%) - Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-publication-results-pivotal-phase-3-trial

Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea

https://investors.modernatx.com/news-releases/news-release-details/moderna-confirms-40-million-covid-19-vaccine-dose-supply

PIPELINE:

$AXSM (-2.15%) - Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-accord-phase-3-trial-axs-05?field_nir_news_date_value[min]=

Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-positive-efficacy-and-safety-0?field_nir_news_date_value[min]=